Influenza vaccine in COVID-19 patients: Who?, why?, when?

1. Ahn D-G, Shin H-J, Kim M-H, Lee S, Kim H-S, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). Journal of Microbiolog and Biotechnology. 2020;30(3): 313–324.10.4014/jmb.2003.03011Search in Google Scholar

2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 Novel Coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395: 565–74.10.1016/S0140-6736(20)30251-8Search in Google Scholar

3. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2): 281–292.e6.10.1016/j.cell.2020.02.058Search in Google Scholar

4. Shah A, Kashyap R, Tosh P, Sampathkumar P, O’Horo JC. Guide to understanding the 2019 novel coronavirus. Mayo Clinic Proceedings. 2020;95: 646–652.10.1016/j.mayocp.2020.02.003Search in Google Scholar

5. Lee VJ, Ho ZJM, Goh EH, Campbell H, Cohen C, et al.; WHO working group on influenza burden of Disease. Advances in measuring influenza burden of disease. Influenza and Other Respiratory Viruses. 2018;12: 3–9.10.1111/irv.12533Search in Google Scholar

6. Who.int. 2021. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. [online] Available at: https://www.who.int/news/item/13-12-2017-up-to-650-000-people-dieof-respiratory-diseases-linked-to-seasonal-flu-each-year.Search in Google Scholar

7. CDC (Center for Disease Control and Prevention). Influenza Type A Viruses; 2017b. https://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm.Search in Google Scholar

8. World Health Organization. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus2019 [Accessed 25th October 2020].Search in Google Scholar

9. Similarities and Differences between Flu and COVID-19. Centers for Disease Control and Prevention; 2020. Available from: https://www.cdc.gov/flu/symptoms/flu-vs-COVID-19.htm. [Accessed 16th November 2020].Search in Google Scholar

10. Wang M, Wu Q, Xu W, Qiao B, Wang J, Zheng H, et al. Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. Medrxiv; Februay 2020. doi:10.1101/2020.02.12.200 22327.Search in Google Scholar

11. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emergency Infectious Diseases. 2020;26(6): 1324–1326.10.3201/eid2606.200299Search in Google Scholar

12. Payan EC, Montagud-Marrahi E, Torres-Elorza M, Bodro M, Blasco M, Poch E, et al. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020;395(10236): e84.10.1016/S0140-6736(20)31052-7Search in Google Scholar

13. Khodamoradi Z, Moghadami M, Lotfi M. Co-infection of corona-virus disease 2019 and influenza A: a report from Iran. Archives of Iranian Medicine. 2020;23(4): 239–243.10.34172/aim.2020.0432271596Search in Google Scholar

14. Ma S, Lai X, Chen Z, Tu S, Qin K. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. International Journal of Infectious Diseases. 2020;96: 683–687.10.1016/j.ijid.2020.05.068725007232470606Search in Google Scholar

15. Xing Q-S, Li G-J, Xing Y-H, Chen T, Li W-J, Ni W, et al. Precautions are Needed for COVID-19 patients with coinfection of common respiratory pathogens. 2020; doi:10.1101/2020.02.29.2002 7698.Search in Google Scholar

16. Singh B, Kaur P, Reid RJ, Shamoon F, Bikkina M. COVID-19 and influenza co-infection: report of three cases. Cureus. 2020;12(8): e9852.10.7759/cureus.9852743709832832306Search in Google Scholar

17. Gostin L, Salmon D. The dual epidemics of COVID-19 and influenza. Published Online: June 11, 2020. doi:10.1001/jama.2020.10802.10.1001/jama.2020.10802Search in Google Scholar

18. People at High Risk of Flu. Centers for disease control and prevention; 2020. Available from: https://www.cdc.gov/flu/highrisk/index.htm. [Accessed 16th November 2020].Search in Google Scholar

19. Eldanasory OA, Rabaan AA, Al-Tawfiq JA. Can influenza vaccine modify COVID-19 clinical course? Travel Medicine and Infectious Disease. 2020;37: 101872.Search in Google Scholar

20. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID- 19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395: 1054–1062.10.1016/S0140-6736(20)30566-3Search in Google Scholar

21. Behrouzi B, Araujo Campoverde M, Liang K, Talbot HK, Bogoch II, McGeer A, et al. Influenza vaccination to reduce cardiovascular morbidity and mortality in patients with COVID-19. Journal of the American College of Cardiology. 2020;76(15): 1777–1794.10.1016/j.jacc.2020.08.028753580933032740Search in Google Scholar

22. Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza vaccination and COVID-19 mortality in the USA. MedRxiv 2020;2020. doi:10.1101/2020.06.24.201 29817. 06.24.20129817.Search in Google Scholar

23. Marín-Hernández D, Schwartz RE, Nixon DF. Epidemiological evidence for association between higher influenza vaccine up-take in the elderly and lower COVID-19 deaths in Italy [published online ahead of print, 2020 Jun 4]. Journal of Medical Virology. 2020; doi:10.1002/jmv.26120.10.1002/jmv.26120730099532497290Search in Google Scholar

24. Blank P, Szucs T. Increasing influenza vaccination coverage in recommended population groups in Europe. Expert Review of Vaccines, 2009;8(4): 425–433.10.1586/erv.09.719348558Search in Google Scholar

25. Ecarnot F, Maggi S, Michel JP. Strategies to Improve Vaccine Uptake throughout Adulthood. Interdiscip Top Gerontol Geriatr. 2020;43:234-248. doi: 10.1159/000504486. PMID: 32305979.10.1159/00050448632305979Search in Google Scholar

26. Sheikh S, Biundo E, Courcier S, Damm O, Launay O, Maes E, et al. A report on the status of vaccination in Europe. Vaccine. 2018;36(33): 4979–4992.10.1016/j.vaccine.2018.06.04430037416Search in Google Scholar

27. Doherty M, Schmidt-Ott R, Santos J, Stanberry L, Hofstetter A, Rosenthal S, et al. Vaccination of special populations: protecting the vulnerable. Vaccine. 2016;34(52): 6681–6690.10.1016/j.vaccine.2016.11.01527876197Search in Google Scholar

28. Lu P, O’Halloran A, Ding H, Srivastav A, Williams W. Uptake of influenza vaccination and missed opportunities among adults with high-risk conditions, United States, 2013. The American Journal of Medicine. 2016;129(6): 636.e1–636.e11.10.1016/j.amjmed.2015.10.031583107826551981Search in Google Scholar

29. Ellingson MK, Dudley MZ, Limaye RJ, Salmon DA, O’Leary ST, Omer SB. Enhancing uptake of influenza maternal vaccine. Expert Review of Vaccines. 2018; doi:10.1080/14760 584.2019.1562907.Search in Google Scholar

30. To K, Lai A, Lee K, Koh D, Lee S. Increasing the coverage of influenza vaccination in healthcare workers: review of challenges and solutions. Journal of Hospital Infection. 2016;94(2): 133–142.10.1016/j.jhin.2016.07.00327546456Search in Google Scholar

31. Zeng Q, Langereis MA, van Vliet ALW, Huizinga EG, de Groot RJ. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proceedings of the National Academy of Sciences of the USA. 2008;105(26): 9065–9069.10.1073/pnas.0800502105244936518550812Search in Google Scholar

32. Abdella R, Aggarwal M, Okura T, Lamb RA, He Y. Structure of a paramyxovirus polymerase complex reveals a unique methyltransferase-CTD conformation. Proceedings of the National Academy of Sciences of the USA 2020;117(9): 4931–4941.10.1073/pnas.1919837117706069932075920Search in Google Scholar

33. Khorramdelazad H, Kazemi MH, Najafi A, Keykhaee M, Emameh RZ, Falak R. Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of co-infection. Microbial Pathogenesis. 2021;152: 104554.10.1016/j.micpath.2020.104554760723533157216Search in Google Scholar

34. Stegemann-Koniszewski S, Behrens S, Boehme JD, Hochnadel I, Riese P, Guzmán CA, et al. Respiratory influenza A virus infection triggers local and systemic natural killer cell activation via toll-like receptor 7. Frontiers in Immunology. 2018;9: 245.10.3389/fimmu.2018.00245581957629497422Search in Google Scholar

35. Poulas K, Farsalinos K, Zanidis C. Activation of TLR7 and innate immunity as an efficient method against COVID-19 pandemic: imiquimod as a potential therapy. Frontiers in Immunology. 2020;11. doi:10.3389/fimmu.2020.01373.10.3389/fimmu.2020.01373730757232612613Search in Google Scholar

36. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Review in Vaccines. 2012;11: 985–994.10.1586/erv.12.61351450623002979Search in Google Scholar

37. Jehi L, Ji X, Milinovich A, Erzurum S, Rubin B, Gordon S, et al. Individualizing risk prediction for positive COVID-19 testing: results from 11,672 patients. Chest. 2020; doi:10.1016/j. chest.2020.05.580.Search in Google Scholar

38. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, Van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature Medicine. 2020;26: 453–455.10.1038/s41591-020-0819-2709503632284614Search in Google Scholar

39. Ellebedy AH, Jackson KJ, Kissick HT, Nakaya HI, Davis CW, Roksin KM, et al. Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nature Immunology. 2016;17: 1226–1234.10.1038/ni.3533505497927525369Search in Google Scholar

40. Koutsakos M, Wheatley AK, Loh L, Clemens EB, Sant S, Nüssing S, et al. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Science Translational Medicine. 2018;10(428): 1–15.10.1126/scitranslmed.aan840529444980Search in Google Scholar

41. Gould V, Francis JN, Anderson KJ, Georges B, Cope AV, Tregoning JS. Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Frontiers in Microbiology, 2017;8: 900.10.3389/fmicb.2017.00900543414428567036Search in Google Scholar

42. Varadhachary A, Chatterjee D, Garza J, Garr RP, Foley C, Letkeman AF, et al. Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. medRxiv [Preprint]. 2020 Aug 11:2020.08.07.20170258. doi: 10.1101/2020.08.07.20170258. PMID: 32817976; PMCID: PMC7430621.10.1101/2020.08.07.20170258743062132817976Search in Google Scholar

43. Debisarun P, Struycken P, Domínguez-Andrés J, et al. The effect of influenza vaccination on trained immunity: impact on COVID-19. MedRXiv. doi:10.1101/2020.10.14.20212498.10.1101/2020.10.14.20212498Search in Google Scholar

44. Horns F, Dekker LC, Quake SR. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Reports. 2020;30: 905–913.10.1016/j.celrep.2019.12.063789155631968262Search in Google Scholar

45. Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer AP, Daubenberger C, et al. Inactivated trivalent influenza vaccine is associated with lower mortality among COVID-19 patients in Brazil. n.d.; doi:10.1101/2020.06.29.20142505.10.1101/2020.06.29.20142505Search in Google Scholar

46. Salem ML, El-Hennawy D. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19 [published online ahead of print, 2020 Apr 22]. Medical Hypotheses. 2020;140: 109752.10.1016/j.mehy.2020.109752719494332361099Search in Google Scholar

47. Li Q, Tang B, Bragazzi NL, Xiao Y, Wu J. Modeling the impact of mass influenza vaccination and public health interventions on COVID-19 epidemics with limited detection capacity. Mathematical Biosciences. 2020;325: 108378.10.1016/j.mbs.2020.108378722976432507746Search in Google Scholar

48. Maltezou HC, Theodoridou K, Poland G. Influenza immunization and COVID-19. Vaccine. 2020;38(39): 6078–6079. doi:10.1016/j.vaccine.2020.07.058.10.1016/j.vaccine.2020.07.058738878032773245Search in Google Scholar

49. Grech V, Borg M. Influenza vaccination in the COVID-19 era. Early Human Development. 2020; doi:10.1016/j.earlhumdev.2020.105116.10.1016/j.earlhumdev.2020.105116730181632604011Search in Google Scholar

50. Thindwa D, Garcia Quesada M, Liu Y, Bennett J, Cohen C, Knoll MD, et al. Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. Vaccine. 2020;38(34): 5398–5401.10.1016/j.vaccine.2020.06.047730365932600911Search in Google Scholar

51. Paget J, Caini S, Cowling B, Esposito S, Falsey AR, Gentile A, et al. The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies. Vaccine. 2020;38(42): 6485–6486.10.1016/j.vaccine.2020.08.024743756532859436Search in Google Scholar